BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/17/2020 3:31:26 AM | Browse: 907 | Download: 1661
 |
Received |
|
2020-02-13 14:27 |
|
Peer-Review Started |
|
2020-02-13 14:28 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-04-03 17:14 |
|
Revised |
|
2020-05-25 01:06 |
|
Second Decision |
|
2020-06-08 09:09 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-06-10 20:04 |
|
Articles in Press |
|
2020-06-10 20:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-07-10 01:52 |
|
Publish the Manuscript Online |
|
2020-07-17 03:31 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Shilpa Srinivasan, Rajesh R Tampi, Kripa Balaram and Arushi Kapoor |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shilpa Srinivasan, MD, Doctor, Doctor, Professor, Department of Neuropsychiatry and Behavioral Science, Palmetto Health USC Medical Group, University of South Carolina School of Medicine, 3555 Harden Street Extension, Suite 301, Columbia, SC 29203, United States. shilpa.srinivasan@uscmed.sc.edu |
| Key Words |
Pimavanserin; Alzheimer’s disease; Psychosis; Psychotic disorders; Antipsychotic agents; |
| Core Tip |
This systematic review was conducted to evaluate the evidence from randomized controlled clinical trials of pimavanserin for the treatment of psychosis in individuals with Alzheimer’s disease (AD). Behavioral disturbances including psychosis are prevalent in AD, and have a significant impact on management and outcomes. There are currently no United States Food and Drug Administration approved medications for the management of behavioral disturbance in AD. Based on the findings of our systematic review, pimavanserin, a novel atypical antipsychotic, may be a new pharmacologic consideration for treating psychosis in individuals with AD. |
| Publish Date |
2020-07-17 03:31 |
| Citation |
Srinivasan S, Tampi RR, Balaram K, Kapoor A. Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review. World J Psychiatr 2020; 10(7): 162-174 |
| URL |
https://www.wjgnet.com/2220-3206/full/v10/i7/162.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v10.i7.162 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
